NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Regulus Therapeutics Inc (NASDAQ: RGLS)
RGLS Technical Analysis
4
As on 9th Jun 2023 RGLS STOCK Price closed @ 1.35 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.92 & Strong Buy for SHORT-TERM with Stoploss of 0.27 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RGLSSTOCK Price
Open | 1.43 | Change | Price | % |
High | 1.45 | 1 Day | -0.07 | -4.93 |
Low | 1.35 | 1 Week | 0.05 | 3.85 |
Close | 1.35 | 1 Month | 0.03 | 2.27 |
Volume | 25600 | 1 Year | 0.99 | 275.00 |
52 Week High 2.39 | 52 Week Low 0.16 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
RGLS Daily Charts |
RGLS Intraday Charts |
Whats New @ Bazaartrend |
RGLS Free Analysis |
|
RGLS Important Levels Intraday
RESISTANCE | 1.54 |
RESISTANCE | 1.48 |
RESISTANCE | 1.44 |
RESISTANCE | 1.40 |
SUPPORT | 1.30 |
SUPPORT | 1.26 |
SUPPORT | 1.22 |
SUPPORT | 1.16 |
RGLS Forecast May 2024
4th UP Forecast | 1.6 |
3rd UP Forecast | 1.52 |
2nd UP Forecast | 1.47 |
1st UP Forecast | 1.42 |
1st DOWN Forecast | 1.28 |
2nd DOWN Forecast | 1.23 |
3rd DOWN Forecast | 1.18 |
4th DOWN Forecast | 1.1 |
RGLS Weekly Forecast
4th UP Forecast | 1.47 |
3rd UP Forecast | 1.43 |
2nd UP Forecast | 1.41 |
1st UP Forecast | 1.38 |
1st DOWN Forecast | 1.32 |
2nd DOWN Forecast | 1.29 |
3rd DOWN Forecast | 1.27 |
4th DOWN Forecast | 1.23 |
RGLS Forecast2024
4th UP Forecast | 5.74 |
3rd UP Forecast | 4.33 |
2nd UP Forecast | 3.46 |
1st UP Forecast | 2.59 |
1st DOWN Forecast | 0.11 |
2nd DOWN Forecast | -0.76 |
3rd DOWN Forecast | -1.63 |
4th DOWN Forecast | -3.04 |
Regulus Therapeutics Inc ( NASDAQ USA Symbol : RGLS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RGLS Other Details
Segment | EQ | |
Market Capital | 39612044.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
RGLS Address
RGLS Latest News
RGLS Business Profile
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 glioblastoma multiforme program; and Hepatitis B virus, non-alcoholic steatohepatitis, and cell therapies programs. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. Address: 4224 Campus Point Court, San Diego, CA, United States, 92121
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service